image

Adoptive Cell Therapy

Innovative Drugs Designed to Improve Patients’ Lives

Our pipeline includes internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. It comprises both Chimeric Targeting Molecules (CTMs) for targeted protein degradation to eliminate disease causing proteins and Ligase Inhibitors that target key control elements in immune regulation. Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of CTMs against a set of unique targets.

Drug-enhanced Cell Therapy Programs

Adoptive Cell Therapy

Nurix is pioneering applying targeted protein modulation to adoptive cell therapy.  Our lead cell therapy program applies a CBL-B inhibitor, NX-0255, to a cancer patient’s T cells outside the body (ex vivo) to enhance their tumor-killing ability when returned to the patient as an autologous cell therapy. Inhibiting CBL-B has several beneficial effects that enhance adoptive T cell therapy, including stimulation of IL-2 secretion, increased T cell proliferation, reduced T cell exhaustion, and a skewing of the phenotype of the T-cells for improved clinical outcomes.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Clinical Pipeline
NX-2127 Degrader BTK + IKZF B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies and autoimmune disease

 

NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition Gynecologic malignancies

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Discovery Pipeline
Wholly Owned Multiple targets* Undisclosed

 

Gilead Sciences 5 targets Undisclosed

 

Sanofi 5 targets Undisclosed

 

Candidate / TargetPhase
Clinical Pipeline
NX-2127 Degrader
BTK + IKZF
Phase 1
NX-5948 Degrader
BTK (Oral)
Phase 1
NX-1607 Inhibitor
CBL-B (Oral)
Phase 1
DeTIL-0255 Cell Therapy
Adoptive cell therapy with ex vivo CBL-B inhibition
Phase 1
Discovery Pipeline
Wholly Owned
Multiple targets*
Discovery
Gilead Sciences
5 targets
Discovery
Sanofi
5 targets
Discovery

DeTIL-0255 (drug-enhanced tumor-infiltrating lymphocytes for solid tumors)

DeTIL-0255 is a cellular therapy that incorporates our proprietary small molecule CBL-B inhibitor NX-0255 in the cell expansion process of tumor infiltrating lymphocytes (TIL). We call this drug-enhanced TIL, or DeTIL. While DeTIL-0255 incorporates a CBL-B inhibitor, we are also exploring combining other targeted agents, such as its proprietary protein degraders, to enhance T cell expansion and phenotypes.

We are planning to first develop DeTIL-0255 in multiple solid tumors as a monotherapy and later to combine it with our proprietary oral CBL-B inhibitor, NX-1607. A Phase 1 clinical trial of DeTIL-0255 in gynecological malignancies is ongoing.